Tirzepatide denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for tirzepatide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Requires Step Therapy for Tirzepatide — and Why You Can Appeal

Step-therapy ("fail-first") denials for tirzepatide from UnitedHealthcare mean the plan requires documented trial and failure of one or more preferred or lower-tier agents before it will authorize tirzepatide. This is one of the most common denial types for branded medications and also one of the most frequently overturned on appeal, particularly when the patient has relevant prior treatment history.

## Why This Denial Is Appealable

Step-therapy requirements are overridable when: (a) you have already tried the required prior medications and they failed or caused adverse effects, (b) a required prior medication is clinically inappropriate for your specific situation per your prescriber's judgment, or (c) requiring the prior steps would create clinically unacceptable delay or risk. Many states have enacted step-therapy exception laws that impose hard deadlines on UHC to respond to exception requests. Additionally, clinical guidelines from organizations such as the ADA or relevant obesity-medicine societies may support tirzepatide as a first-line or early-line option in certain patient profiles, which is relevant evidence.

## Federal Appeal Framework

• Internal appeal: ERISA §503 (employer plans) or applicable state law requires a full-and-fair internal review. File by the deadline on your denial letter — typically 180 days. Request UHC's step-therapy policy and the complete list of required prior agents.
• External review: Under ACA §2719, step-therapy denials are eligible for independent external review after internal remedies are exhausted. The window is generally within approximately four months of the final internal denial. External reviewers apply clinical standards.
• Expedited review: Available when delay would seriously jeopardize health; typically decided within 72 hours.

## Concrete Appeal Steps

1. Obtain the denial letter and UHC's step-therapy policy — identify every required prior agent. 2. With your prescriber, audit your complete medication history against the required list. 3. For each required prior agent you have tried, document the dates, clinical response, and reason for discontinuation from chart records and pharmacy records. 4. For any required prior agent you have not tried, ask your prescriber to document a clinical reason it is inappropriate — allergy, interaction concern, or clinical contraindication per the prescribing label; the prescriber makes this clinical call. 5. Submit a step-therapy exception request (if UHC has a formal process) along with your internal appeal. 6. If denied, file for external review.

## Documentation to Gather

• Complete medication history: Pharmacy printout and chart notes covering every relevant prior medication, with start dates, end dates, doses, and clinical outcomes.
• Prescriber medical-necessity letter: Addresses each required step-therapy agent individually — confirming trial and failure, or documenting clinical reason for non-use.
• Diagnosis and severity records: Chart documentation establishing the underlying condition and its severity, supporting urgency of effective treatment.
• Guideline-organization reference: Your prescriber should cite the applicable guideline organization (ADA, relevant obesity-medicine society, or other) to establish that tirzepatide is a recognized appropriate treatment for your clinical profile.

## Criteria-Mapping Structure

List each step-therapy requirement from UHC's policy verbatim in the left column of a table. In the right column, provide the specific chart-based response: documented failure of the prior agent (with dates and pharmacy records), or the prescriber's documented clinical rationale for why the agent is inappropriate. Attach pharmacy records, chart notes, and the prescriber letter as labeled exhibits. This one-to-one mapping forces UHC's reviewer to engage with each requirement individually and significantly reduces reviewer discretion.